Prediction markets are built on a simple promise - if people can freely trade on outcomes, the market will aggregate ...

Speaking at WSJ Opinion Live in Washington, D.C., WSJ Editorial Page Editor Paul Gigot and SandboxAQ CEO Jack Hidary discuss Large Quantitative Models (LQMs) and their role in AI applications, the ...

An investigator-initiated phase II trial of a PARP inhibitor niraparib monotherapy for patients with pre-treated, BRCA-mutated, unresectable/recurrent biliary tract, pancreatic, and other ...

David Toro-Tobon and colleagues argue that “clinician in the loop” is shifting responsibility for AI safety from developers ...

This purchase is available as a free download with your MyC-SPAN account. :::downloadsRemaining::: :::basketAlert::: Watch unfiltered coverage of Congress, the White ...

Exclusive: It follows numerous complaints made to Guardian Australia, politicians and advocacy organisations about the Integrated Assessment Tool Follow our Australia news live blog for latest updates ...

Find weekly sales, monthly deals, discounts and more from your favorite retailers. Shop beauty, pets, jewelry, apparel, tech, wellness and more. Shop deals on DIY craft machines, spring apparel, ...

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3 A total of 160 patients ...

Post-thrombotic syndrome is common after deep-vein thrombosis and can cause severe symptoms involving the limbs that impair patients’ activity and quality of life. Endovascular therapy can eliminate ...

Ohio-based aerospace company SelectTech Services Corporation is expanding to Colorado Springs. Company leadership, Gov. Jared Polis and local business and economic development officials announced the ...

Short-term headwinds, long-term edge. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on ...

In this multicenter, open-label, randomized, controlled trial in China, we assigned participants with newly diagnosed Kawasaki disease in a 1:1 ratio to receive prednisolone plus standard treatment or ...